Volume 14 Issue 2
Mar.  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(2): 220-226
Wang Yuchen, Miao Yun. Management of diarrhea after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 220-226. doi: 10.3969/j.issn.1674-7445.2023.02.007
Citation: Wang Yuchen, Miao Yun. Management of diarrhea after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 220-226. doi: 10.3969/j.issn.1674-7445.2023.02.007
shu

Management of diarrhea after kidney transplantation

doi: 10.3969/j.issn.1674-7445.2023.02.007

  • Department of Organ Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

More Information
  • Corresponding author: Miao Yun, Email: miaoyunecho@126.com
  • Received Date: 2022-11-01
    Available Online: 2023-03-15
  • Publish Date: 2023-03-15
    Abstract
  • Diarrhea is a frequent complication after kidney transplantation, which is a common clinical manifestation of prevalent diseases following multiple types of organ transplantation. The common causes of diarrhea after kidney transplantation include adverse reactions of immunosuppressants, infectious diseases and de novo postoperative inflammatory bowel disease, etc. Diarrhea could seriously affect the quality of life of kidney transplant recipients, and may lead to allograft dysfunction or even death of recipients. Because the causes of diarrhea after kidney transplantation are complicated and probably overlap with each other, along with individual differences among recipients, the etiological diagnosis and targeted treatment of diarrhea after kidney transplantation should follow the principles of gradual and phased treatment. In this article, the epidemiology and harm, common causes and management strategies of diarrhea after kidney transplantation were summarized, aiming to deepen the clinicians' understanding and enhance the diagnosis and treatment levels of diarrhea after kidney transplantation, thereby improving the quality of life and prognosis of kidney transplant recipients.

     

    • FullText(HTML)
  • loading
    • References(56)
  • [1]
    GIL-VERNET S, AMADO A, ORTEGA F, et al. Gastrointestinal complications in renal transplant recipients: MITOS study[J]. Transplant Proc, 2007, 39(7): 2190-2193. DOI: 10.1016/j.transproceed.2007.07.015.
    [2]
    GIBSON CM, CHILDS-KEAN LM, NAZIRUDDIN Z, et al. The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation[J]. Transpl Infect Dis, 2021, 23(1): e13397. DOI: 10.1111/tid.13397.
    [3]
    GABARRE P, LOENS C, TAMZALI Y, et al. Immunosuppressive therapy after solid organ transplantation and the gut microbiota: bidirectional interactions with clinical consequences[J]. Am J Transplant, 2022, 22(4): 1014-1030. DOI: 10.1111/ajt.16836.
    [4]
    ANGARONE M, ISON MG. Diarrhea in solid organ transplant recipients[J]. Curr Opin Infect Dis, 2015, 28(4): 308-316. DOI: 10.1097/QCO.0000000000000172.
    [5]
    EKBERG H, KYLLÖNEN L, MADSEN S, et al. Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: a multinational survey of nephrologists[J]. Transplantation, 2007, 84(8): 1052-1054. DOI: 10.1097/01.tp.0000284983.89207.1a.
    [6]
    ALTIPARMAK MR, TRABLUS S, PAMUK ON, et al. Diarrhoea following renal transplantation[J]. Clin Transplant, 2002, 16(3): 212-216. DOI: 10.1034/j.1399-0012.2002.01129.x.
    [7]
    ECHENIQUE IA, PENUGONDA S, STOSOR V, et al. Diagnostic yields in solid organ transplant recipients admitted with diarrhea[J]. Clin Infect Dis, 2015, 60(5): 729-737. DOI: 10.1093/cid/ciu880.
    [8]
    SINGH M, HEINCELMAN M. Disseminated nontuberculous mycobacterium presenting as chronic diarrhea and wasting[J]. J Investig Med High Impact Case Rep, 2022, 10: 23247096221101860. DOI: 10.1177/23247096221101860.
    [9]
    WANG HY, YEH MK, TIAN YF, et al. Effect of prolonged diarrhea in renal transplant recipients at a single center in Taiwan[J]. Transplant Proc, 2016, 48(3): 870-873. DOI: 10.1016/j.transproceed.2015.12.075.
    [10]
    TANAKA R, MATSUMOTO A, TATSUTA R, et al. Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial-associated diarrhea in a kidney transplant recipient with Crohn's disease: a case report[J]. Clin Case Rep, 2022, 10(6): e05914. DOI: 10.1002/ccr3.5914.
    [11]
    BELGA S. Chronic diarrhea secondary to norovirus infection in kidney transplant recipients: early recognition is key[J]. Transplantation, 2021, 105(12): 2524-2525. DOI: 10.1097/TP.0000000000003709.
    [12]
    VYAS VD, PARAMESWARAN SA, PARAMASIVAN P, et al. Etiological profile of diarrhea in solid organ transplant recipients at a tertiary care center in Southern India[J]. Transpl Infect Dis, 2021, 23(4): e13584. DOI: 10.1111/tid.13584.
    [13]
    SEKMEK S, YILDIRIM T, KOC NS, et al. Efficacy and safety of switching to azathioprine for mycophenolate-induced diarrhea in renal transplant recipients[J]. Transplant Proc, 2021, 53(6): 1951-1956. DOI: 10.1016/j.transproceed.2021.06.020.
    [14]
    JARDOU M, PROVOST Q, BROSSIER C, et al. Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model[J]. BMC Pharmacol Toxicol, 2021, 22(1): 66. DOI: 10.1186/s40360-021-00536-4.
    [15]
    CALMET FH, YARUR AJ, PUKAZHENDHI G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation[J]. Ann Gastroenterol, 2015, 28(3): 366-373.
    [16]
    BHATTACHARYA S, STOLERU G, PATEL P, et al. Characterization of mycophenolate mofetil gastrointestinal toxicity and risk factors for severe disease and poor prognosis[J]. Inflamm Bowel Dis, 2022, 28(5): 811-814. DOI: 10.1093/ibd/izab254.
    [17]
    HISSONG E, MOSTYKA M, YANTISS RK. Histologic features of tacrolimus-induced colonic injury[J]. Am J Surg Pathol, 2022, 46(1): 118-123. DOI: 10.1097/PAS.0000000000001761.
    [18]
    ALKHATIB AA. Sirolimus-induced intractable chronic diarrhea: a case report[J]. Transplant Proc, 2006, 38(5): 1298-1300. DOI: 10.1016/j.transproceed.2006.02.123.
    [19]
    ARSLAN H, INCI EK, AZAP OK, et al. Etiologic agents of diarrhea in solid organ recipients[J]. Transpl Infect Dis, 2007, 9(4): 270-275. DOI: 10.1111/j.1399-3062.2007.00237.x.
    [20]
    AULAGNON F, SCEMLA A, DEWOLF S, et al. Diarrhea after kidney transplantation: a new look at a frequent symptom[J]. Transplantation, 2014, 98(8): 806-816. DOI: 10.1097/TP.0000000000000335.
    [21]
    ORTIZ-BALBUENA J, ROYUELA A, CALDERÓN-PARRA J, et al. Risk factors for clostridioides difficile diarrhea in solid organ transplantation recipients[J]. Transplant Proc, 2021, 53(10): 2826-2832. DOI: 10.1016/j.transproceed.2021.09.047.
    [22]
    HOSSEINI-MOGHADDAM SM, LUO B, BOTA SE, et al. Incidence and outcomes associated with clostridioides difficile infection in solid organ transplant recipients[J]. JAMA Netw Open, 2021, 4(12): e2141089. DOI: 10.1001/jamanetworkopen.2021.41089.
    [23]
    ROOS-WEIL D, AMBERT-BALAY K, LANTERNIER F, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea[J]. Transplantation, 2011, 92(1): 61-69. DOI: 10.1097/TP.0b013e31821c9392.
    [24]
    SCHORN R, HÖHNE M, MEERBACH A, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution[J]. Clin Infect Dis, 2010, 51(3): 307-314. DOI: 10.1086/653939.
    [25]
    JORGENSON MR, DESCOUROUEZ JL, KLEIBOEKER H, et al. Cytomegalovirus antiviral stewardship in solid organ transplant recipients: a new gold standard[J]. Transpl Infect Dis, 2022, 24(5): e13864. DOI: 10.1111/tid.13864.
    [26]
    KOTTON CN, TORRE-CISNEROS J, International CMV Symposium Faculty, et al. Cytomegalovirus in the transplant setting: where are we now and what happens next? a report from the International CMV Symposium 2021[J]. Transpl Infect Dis, 2022, 24(6): e13977. DOI: 10.1111/tid.13977.
    [27]
    HOGAN JI, STEINER KL, SIFRI CD. First report of sexually transmitted primary cytomegalovirus proctocolitis in a renal transplant recipient[J]. Transpl Infect Dis, 2022, 24(1): e13680. DOI: 10.1111/tid.13680.
    [28]
    FERGUSON J, MOONEY K, SALEEM A, et al. Cutaneous cytomegalovirus - a case of disseminated cytomegalovirus presenting with extensive ulcerative skin lesions in a renal transplant recipient[J]. Transpl Infect Dis, 2021, 23(4): e13582. DOI: 10.1111/tid.13582.
    [29]
    YANG QH, MA XP, DAI DL, et al. Gastrointestinal cytomegalovirus disease secondary to measles in an immunocompetent infant: a case report[J]. World J Gastroenterol, 2021, 27(15): 1655-1663. DOI: 10.3748/wjg.v27.i15.1655.
    [30]
    ABBAS A, ZIMMER AJ, FLORESCU D. Viral enteritis in solid-organ transplantation[J]. Viruses, 2021, 13(10): 2019. DOI: 10.3390/v13102019.
    [31]
    ARREGUI GARCIA I, ELÍA LÒPEZ M, AGUINAGA PÉREZ A, et al. Cryptosporidiosis in immunosuppressed renal transplant patient[J]. Rev Esp Quimioter, 2021, 34(2): 164-166. DOI: 10.37201/req/136.2020.
    [32]
    SENEGHINI M, PETERMICHL V, FREI R, et al. Microsporidiosis in a solid organ transplant recipient[J]. Int J Infect Dis, 2021, 108: 18-19. DOI: 10.1016/j.ijid.2021.04.084.
    [33]
    GIOCO R, CORONA D, EKSER B, et al. Gastrointestinal complications after kidney transplantation[J]. World J Gastroenterol, 2020, 26(38): 5797-5811. DOI: 10.3748/wjg.v26.i38.5797.
    [34]
    SEN A, CALLISEN H, LIBRICZ S, et al. Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal[J]. Crit Care Clin, 2019, 35(1): 169-186. DOI: 10.1016/j.ccc.2018.08.011.
    [35]
    AXELRAD JE, CADWELL KH, COLOMBEL JF, et al. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211004493. DOI: 10.1177/17562848211004493.
    [36]
    SAMPAIO MS, CHO YW, QAZI Y, et al. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database[J]. Transplantation, 2012, 94(10): 990-998. DOI: 10.1097/TP.0b013e318270bc7b.
    [37]
    SPRANGERS B, RIELLA LV, DIERICKX D. Posttransplant lymphoproliferative disorder following kidney transplantation: a review[J]. Am J Kidney Dis, 2021, 78(2): 272-281. DOI: 10.1053/j.ajkd.2021.01.015.
    [38]
    KATZ-GREENBERG G, GHIMIRE S, ZHAN T, et al. Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature[J]. Am J Cancer Res, 2021, 11(9): 4624-4637.
    [39]
    MAES B, HADAYA K, DE MOOR B, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study[J]. Am J Transplant, 2006, 6(6): 1466-1472. DOI: 10.1111/j.1600-6143.2006.01320.x.
    [40]
    BUNNAPRADIST S, LENTINE KL, BURROUGHS TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure[J]. Transplantation, 2006, 82(1): 102-107. DOI: 10.1097/01.tp.0000225760.09969.1f.
    [41]
    MULLANE KM, DUBBERKE ER, AST ID Community of Practice. Management of clostridioides (formerly clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation Community of Practice[J]. Clin Transplant, 2019, 33(9): e13564. DOI: 10.1111/ctr.13564.
    [42]
    MAHATANAN R, TANTISATTAMO E, CHAROENPONG P, et al. Outcomes of C difficile infection in solid-organ transplant recipients: the National Inpatient Sample (NIS) 2015-2016[J]. Transpl Infect Dis, 2021, 23(1): e13459. DOI: 10.1111/tid.13459.
    [43]
    DUDZICZ-GOJOWY S, WIĘCEK A, ADAMCZAK M. Clostridioides difficile infection in patients after organ transplantation-a narrative overview[J]. J Clin Med, 2022, 11(15): 4365. DOI: 10.3390/jcm11154365.
    [44]
    REIGADAS E, VAN PREHN J, FALCONE M, et al. How to: prophylactic interventions for prevention of clostridioides difficile infection[J]. Clin Microbiol Infect, 2021, 27(12): 1777-1783. Doi: 10.1016/j.cmi.2021.06.037.
    [45]
    MCDONALD LC, GERDING DN, JOHNSON S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) [J]. Clin Infect Dis, 2018, 66(7): 987-994. DOI: 10.1093/cid/ciy149.
    [46]
    KHORUTS A, STALEY C, SADOWSKY MJ. Faecal microbiota transplantation for clostridioides difficile: mechanisms and pharmacology[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 67-80. DOI: 10.1038/s41575-020-0350-4.
    [47]
    CHENG YW, PHELPS E, GANAPINI V, et al. Fecal microbiota transplantation for the treatment of recurrent and severe clostridium difficile infection in solid organ transplant recipients: a multicenter experience[J]. Am J Transplant, 2019, 19(2): 501-511. DOI: 10.1111/ajt.15058.
    [48]
    DURAND CM, MARR KA, ARNOLD CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients[J]. Clin Infect Dis, 2013, 57(11): 1550-1559. DOI: 10.1093/cid/cit521.
    [49]
    RUENROENGBUN N, NUMTHAVAJ P, SAPANKAEW T, et al. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis[J]. Transpl Int, 2021, 34(12): 2720-2734. DOI: 10.1111/tri.14122.
    [50]
    RAZONABLE RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients[J]. Infect Dis Clin North Am, 2013, 27(2): 317-342. DOI: 10.1016/j.idc.2013.02.005.
    [51]
    RAZONABLE RR, HUMAR A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13512. DOI: 10.1111/ctr.13512.
    [52]
    HELLEMANS R, ABRAMOWICZ D. Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention[J]. Nephrol Dial Transplant, 2022, 37(5): 810-816. DOI: 10.1093/ndt/gfaa249.
    [53]
    HAKKI M. Moving past ganciclovir and foscarnet: advances in CMV therapy[J]. Curr Hematol Malig Rep, 2020, 15(2): 90-102. DOI: 10.1007/s11899-020-00557-6.
    [54]
    OKI R, HIDAKA S, SASAKI A, et al. De novo ulcerative colitis after kidney transplantation treated with infliximab[J]. CEN Case Rep, 2021, 10(4): 500-505. DOI: 10.1007/s13730-021-00599-6.
    [55]
    PEVERELLE M, ASADI K, DE CRUZ P. Ustekinumab is a safe and effective biological agent for Crohn's disease in a liver transplant patient[J]. J Crohns Colitis, 2020, 14(10): 1498-1499. DOI: 10.1093/ecco-jcc/jjaa062.
    [56]
    INDRIOLO A, RAVELLI P. Clinical management of inflammatory bowel disease in the organ recipient[J]. World J Gastroenterol, 2014, 20(13): 3525-3533. DOI: 10.3748/wjg.v20.i13.3525.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1877) PDF downloads(268) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return